Dr. Scheller has served as a member of our Board since March 2015. Dr. Scheller has been Chief Science Officer at 23andMe, a personal genetics company, since 2015. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc. from February 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd. Since November 2018, Dr. Scheller has served as a member of the board of directors for Alector, Inc., a publicly-traded biopharmaceutical company. Since January 2018, Dr. Scheller has served as a member of the board of directors of BridgeBio Inc. and, since February 2015, as a member of the board of directors for ORIC Pharmaceuticals, Inc. Dr. Scheller is a former member of the board of directors for Affinita Biotech, Inc. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University.